EGFR and non-small cell lung carcinoma: Since NSCLC EGFR-TKI therapy blocks the activation of EGFR, we evaluated expression levels of p-EGFR, a molecular correlate of EGFR activity, and its downstream effectors, p-ERK and p-Akt, in HCC827 cells in mono- and co-culture with MRC-5 cells.